US Stock MarketDetailed Quotes
ACTU Actuate Therapeutics
- 7.130
- -0.330-4.42%
Close Oct 7 16:00 ET
139.26MMarket Cap-2762P/E (TTM)
7.500High6.800Low95.30KVolume7.290Open7.460Pre Close680.52KTurnover3.40%Turnover RatioLossP/E (Static)19.53MShares10.16252wk High-1.22P/B19.96MFloat Cap5.51052wk Low--Dividend TTM2.80MShs Float10.162Historical High--Div YieldTTM9.38%Amplitude5.510Historical Low7.141Avg Price1Lot Size
Actuate Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | ||||||
| Gross profit | ||||||
| Operating expense | 0.91%5.64M | 50.48%7.97M | 23.59%24.97M | 5.58M | 5.3M | 20.21M |
| Selling and administrative expenses | 56.43%1.26M | 43.63%1.11M | -14.51%3.27M | --807.18K | --774.8K | --3.82M |
| -General and administrative expense | 56.43%1.26M | 43.63%1.11M | -14.51%3.27M | --807.18K | --774.8K | --3.82M |
| Research and development costs | -8.47%4.37M | 51.65%6.86M | 32.47%21.71M | --4.78M | --4.52M | --16.39M |
| Operating profit | -0.91%-5.64M | -50.48%-7.97M | -23.59%-24.97M | -5.58M | -5.3M | -20.21M |
| Net non-operating interest income expense | -96.77%3.57K | -58.14%9.71K | 2,754.26%309.03K | 110.33K | 23.2K | 10.83K |
| Non-operating interest income | -92.51%8.65K | -71.37%14.79K | 1,204.89%352.67K | --115.39K | --51.65K | --27.03K |
| Non-operating interest expense | 0.28%5.08K | -82.16%5.08K | 169.39%43.64K | --5.06K | --28.45K | --16.2K |
| Other net income (expense) | -1,773.41%-940.34K | -6,614.79%-332.52K | -318.22%-79.82K | -50.19K | 5.1K | 36.58K |
| Gain on sale of security | -378.82%-240.34K | -737.05%-32.52K | -318.22%-79.82K | ---50.19K | --5.1K | --36.58K |
| Other non- operating income (expenses) | ---700K | ---300K | ---- | ---- | ---- | ---- |
| Income before tax | -18.97%-6.57M | -57.41%-8.3M | -22.74%-24.74M | -5.52M | -5.27M | -20.16M |
| Income tax | ||||||
| Net income | -18.97%-6.57M | -57.41%-8.3M | -22.74%-24.74M | -5.52M | -5.27M | -20.16M |
| Net income continuous Operations | -18.97%-6.57M | -57.41%-8.3M | -22.74%-24.74M | ---5.52M | ---5.27M | ---20.16M |
| Minority interest income | ||||||
| Net income attributable to the parent company | -18.97%-6.57M | -57.41%-8.3M | -22.74%-24.74M | -5.52M | -5.27M | -20.16M |
| Preferred stock dividends | ||||||
| Other preferred stock dividends | ||||||
| Net income attributable to common stockholders | -18.97%-6.57M | -57.41%-8.3M | -22.74%-24.74M | -5.52M | -5.27M | -20.16M |
| Basic earnings per share | 3.58%-0.3439 | -58.71%-0.54 | -23.05%-1.65 | -0.3566 | -0.3402 | -1.3409 |
| Diluted earnings per share | 3.58%-0.3439 | -58.71%-0.54 | -23.05%-1.65 | -0.3566 | -0.3402 | -1.3409 |
| Dividend per share | ||||||
| Currency Unit | USD | USD | USD | USD | USD | USD |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
